This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colao, A. Articles by Fenzi, G. Search for Related Content PubMed PubMed Citation Articles by Colao, A. Articles by Fenzi, G.

Orbital Scintigraphy with [¹¹¹In-Diethylenetriamine Pentaacetic Acid-D-Phe¹]-Octreotide Predicts the Clinical Response to Corticosteroid Therapy in Patients with Graves’ Ophthalmopathy

Departments of Molecular and Clinical Endocrinology and Oncology (A.C., D.F., R.P., P.E.M., G.L., G.F.) and Ophthalmology (P.V., G.B.), Federico II University, and Nuclear Medicine, INT G. Pascale (S.L., P.M.), Naples, Italy

Address correspondence and requests for reprints to: Annamaria Colao, Department of Molecular and Clinical, Endocrinology and Oncology, "Federico II", University, Via Sergio Pansini, 5 80131, Naples, Italy.

Corticosteroid treatment is successfully used in Graves’ ophthalmopathy, and its effect varies according to the phase of the disease. The infiltration of the orbit by activated lymphocytes may explain the effectiveness of corticosteroid therapy. Scintigraphy with [¹¹¹In-DTPA-D-Phe¹]-octreotide was recently used to reveal the presence of activated lymphocytes in foci of autoimmune diseases, because elevated amounts of somatostatin receptors are expressed in the surface of these cells. The aim of the current study was to evaluate whether the degree of orbital [¹¹¹In-DTPA-D-Phe¹]-octreotide uptake is able to predict the response to corticosteroid therapy in patients with Graves’ ophthalmopathy.

Ten patients with Graves’ ophthalmopathy entered the study. In all patients scintigraphy was performed, and subsequently, corticosteroid therapy (methylprednisolone, 1 g iv for 2 consecutive days a week for 6 weeks) was given. Clinical activity of Graves’ ophthalmopathy was evaluated before and after treatment by calculating the ophthalmopathy index (OI). Planar and single photon emission computed tomography (SPECT) images of the head were obtained 24 h after the iv injection of 120–190 MBq of [¹¹¹In-DTPA-D-Phe¹]-octreotide. Radioligand uptake within each orbit (O) and brain (B) was measured using the region of interests (ROI) method and the O-to-B ratio was determined. According to the O-to-B ratio, the images were classified using the following three points score: 0 = O-to-B ratio 1; 1 = O-to-B ratio between 1 and 2.5; 2 = O-to-B ratio 2.5. The value of OI, measured before and after corticosteroid treatment, was correlated to the scintigraphic score.

A significant change of OI was observed between posttreatment and pretreatment evaluation both in orbits with score 2 (OI: 15.4 ± 1.5 vs. 9.6 ± 0.5, P < 0.005) and in those with score 1 or 0 (OI: 12.9 ± 1.5 vs. 11.5 ± 1.4, P < 0.05) at the scintigraphy. However, when the OI was calculated excluding the changes in the soft tissue, which generally occur in all patients independently from the phase of the disease, a significant change of OI was observed only in the orbits with score 2 (OI: 12.9 ± 1.3 vs. 8.3 ± 0.5, P < 0.01) but not in those with score 0 or 1 (OI: 11.2 ± 1.3 vs. 10.4 ± 1.3). In particular, 6 weeks after corticosteroid treatment, the patients with orbital score 2 at the scintigraphy had a significant improvement of soft tissue changes, proptosis, lagophthalmos, extraocular muscle movements impairment, and diplopia, whereas patients with score 0 or 1 had only a significant improvement of the soft tissue inflammation.

In conclusion, the current preliminary data suggested that [¹¹¹In-DTPA-D-Phe¹]-octreotide scintigraphy is able to predict the clinical response to corticosteroid treatment in patients with Graves’ ophthalmopathy, and may be considered an useful approach to select the patients for the proper treatment.

This article has been cited by other articles:

				M. N. Stan, J. A. Garrity, E. A. Bradley, J. J. Woog, M. M. Bahn, M. D. Brennan, S. C. Bryant, S. J. Achenbach, and R. S. Bahn Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4817 - 4824. [Abstract] [Full Text] [PDF]

				S. Savastano, R. Pivonello, W. Acampa, M. Salvatore, G. Lombardi, A. Colao, and G. Fenzi Recombinant Thyrotropin-Induced Orbital Uptake of [111In-Diethylenetriamine-Pentacetic Acid-D-Phe1]Octreotide in a Patient with Inactive Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2440 - 2444. [Abstract] [Full Text] [PDF]

				J. L. Wemeau, P. Caron, A. Beckers, V. Rohmer, J. Orgiazzi, F. Borson-Chazot, M. Nocaudie, P. Perimenis, S. Bisot-Locard, I. Bourdeix, et al. Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves' Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 841 - 848. [Abstract] [Full Text] [PDF]

				D. Pasquali, A. Notaro, G. Bonavolonta', P. Vassallo, A. Bellastella, and A. A. Sinisi Somatostatin Receptor Genes Are Expressed in Lymphocytes from Retroorbital Tissues in Graves' Disease J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5125 - 5129. [Abstract] [Full Text] [PDF]

				C. Marcocci, L. Bartalena, M. L. Tanda, L. Manetti, E. Dell'Unto, R. Rocchi, G. Barbesino, B. Mazzi, M. P. Bartolomei, P. Lepri, et al. Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves' Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3562 - 3567. [Abstract] [Full Text] [PDF]

				L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]